[Summary] AAV research and development manufacturer
Founded in 2014 by a group of like-minded scientists, Vigene Biosciences is driven by the mission to make gene therapy affordable for everyone and to bring this transformative treatment to patients worldwide. Facing the immense potential of AAV vector therapy and the challenges of high costs and technical barriers in traditional processes, Vigene is committed to driving innovation in AAV production and the broader gene therapy field, making high efficiency, scalable production, and low cost a reality.
As a leading CRO & CDMO, Vigene Biosciences provides one-stop solutions from vector design and construction to AAV, lentivirus, and mRNA services, covering early proof-of-concept, druggability assessment, and various stages including IIT, IND, and BLA. After years of intensive research, Vigene's R&D team has developed the π-Alpha™ 293 cell AAV high-yield platform, which significantly reduces drug development costs while ensuring product quality, boosting AAV yield by 10-fold, and achieving up to 1E+17 vg per single-batch, single-tank production.
At Vigene, the significance of technological innovation lies in helping clients turn impossible stories into possible realities. We have witnessed firsthand how gene therapy rewrites the scripts of life: children with Rett syndrome regain vitality, families affected by ALS find hope, and patients with retinoschisis see a clearer world. Most touching is the story of a congenitally deaf boy who, after receiving AAV gene therapy produced by Vigene, heard his family's voices for the first time. Months later, he clearly spoke his first word, "Daddy," and his father's tears of joy reinforced our belief that this is not just a technological breakthrough but a beacon of hope rekindled for countless patients and families.
Today, Vigene Biosciences has become a leading gene therapy CRO & CDMO, serving over 30 countries and partnering with more than 2,000 biopharmaceutical companies and research institutions. "Making gene therapy affordable for everyone" is not just a slogan but a principle we practice. We will continue to tackle core challenges such as viral vector production, targeted delivery, mRNA technology, and large-scale GMP manufacturing, empowering global partners through reliable and efficient service systems and technical support, and contributing to human health together.
Company website: *
What does Guangzhou Vigene Biosciences Co., Ltd. require? Who is Vigene Biosciences hiring? Vigene Biosciences recruitment: 销售类占比最多占48.1%，其次是科研类占43%. What education can get in at Vigene Biosciences? 本科占比最多占65.8%，其次是硕士占13.9%. High education required at Vigene Biosciences? 硕士占13.9%，博士占12.7%. Work experience required at Vigene Biosciences? 不限占比最多占43%，其次是1-3年占34.2%. Where are the job locations at Vigene Biosciences? 广州占比最多占59.5%，其次是北京占11.4%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
